Annual Drug Patent Expirations for AMELUZ
Ameluz is a drug marketed by Biofrontera and is included in one NDA. It is available from one supplier. There is one patent protecting this drug.
This drug has one patent family member in one country.
The generic ingredient in AMELUZ is aminolevulinic acid hydrochloride. One supplier is listed for this compound. Additional details are available on the aminolevulinic acid hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com